Publications

5674 Results

Epothilone B (Epo-B) analogue BMS-247550 (NSC# 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology Group study (S0111)

Authors
M Hussain;J Faulkner;U Vaishampayan;P Lara;D Petrylak;D Colevas;W Sakr;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 23:383 (#4510)
Year
2004
Research Committee(s)
Genitourinary
Study Number(s)
S0111

Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126.

Authors
H West;WA Franklin;PH Gumerlock;RB Vance;DHM Lau;J McCoy;J Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 23:618 (#7014)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0126

Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)

Authors
L Garland;C Rankin;K Scott;R Nagle;M Lobell;D Gandara;S Rivkin;W Samlowski;J Atkins;E Borden
Journal / Conference
Proc of the American Society of Clincial Oncology 23:196 (#3007)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0218

Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 bladder cancer - a Southwest Oncology Group Trial

Authors
SP Lerner;C Tangen;H Sucharew;D Wood;ED Crawford
Journal / Conference
Journal of Urology 171(Suppl 4):72(#273)
Year
2004
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8507

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Authors
DP Petrylak;CM Tangen;MHA Hussain;PN Lara Jr;JA Jones;ME Taplin;PA Burch;D Berry;C Moinpour;M Kohli;MC Benson;EJ Small;D Raghavan;ED Crawford
Journal / Conference
New England Journal of Medicine 351(15):1513-1520
Year
2004
Research Committee(s)
Genitourinary
Study Number(s)
S9916

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

Authors
G Arpino;SJ Green;DC Allred;D Lew;S Martino;CK Osborne;RM Elledge
Journal / Conference
Clinical Cancer Research 10:5670-5676
Year
2004
Research Committee(s)
Breast
Study Number(s)
SWOG-9314

Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited stage small cell lung cancer (S0004): a Southwest Oncology Group study

Authors
QT Le;J McCoy;S Williamson;J Ryu;LE Gaspar;M Edelman;S Dakhil;SD Sides;JJ Crowley;DR Gandara
Journal / Conference
Clinical Cancer Research 10:5418-5424
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0004

Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: a phase II study of the Southwest Oncology Group

Authors
HO Smith;C Jiang;GR Weiss;AV Hallum;PY Liu;AM Miller;DR Gandara;M Markman;DS Alberts
Journal / Conference
Gynecologic Oncology 92:416 (#49)
Year
2004
Research Committee(s)
Gynecologic
Study Number(s)
S9717

Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter

Authors
IM Thompson;DK Pauler;PJ Goodman;CM Tangen;MS Lucia;HL Parnes;LM Minasian;LG Ford;SM LIppman;ED Crawford;JJ Crowley;CA Coltman Jr
Journal / Conference
New England Journal of Medicine 350(22):2239-2246
Year
2004
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Surgical factors influence bladder cancer outcomes: a Cooperative Group report

Authors
HW Herr;JR Faulkner;HB Grossman;RB Natale;R de Vere White;MF Sarosdy;ED Crawford
Journal / Conference
Journal of Clinical Oncology 22(14):2781-2789
Year
2004
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)